Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
The EU Framework Programme for Research and Innovation HORIZON 2020 OVERVIEW OF RESEARCH ACTIVITIES IN INFECTIOUS DISEASES OCTA - European Parliament 20th October 2015 Inmaculada Peñas Jiménez 'Fighting Infectious Diseases and Global Epidemics DG Research & Innovation European Commission 1 The role of the European Commission Research and innovation Develop and implement the European research and innovation policy agreed by the European Parliament and European Council. Funds research through multi-annual framework programmes for research (since 1984). Implemented through annual work programmes and call for proposals and independent peer review of proposals. The European Commission manages about 5% of total public spending in R&D in the European Union. 2 Key priorities for infectious diseases in the Health, Demographic Change and Wellbeing Theme • Emerging infectious diseases (EE) Influenza and other emerging diseases (incl vector-borne diseases) • Anti-microbial resistance (AMR) • Poverty-related diseases (PRD) HIV/AIDS, Tuberculosis, Malaria • Neglected Infectious diseases (NID) 3 Some figures of the research in major infectious diseases funded by the FP7 (2007-2013) 4 Some FP7 projects… • IDAMS € 6 million EU contribution - Start 01/09/2011 - 60 months • Is improving clinical and laboratory diagnosis and clinical management of dengue; identifying markers to differentiate dengue from other febrile illness; likelihood to evolve to a more severe disease; risk of dengue spread and maps; and developing effective and affordable early warning systems and outbreak responses • 18 participants from 14 countries including from Mexico,Malaysia and Ghana • DENGUETOOLS € 6 million EU contribution - Start 01/09/2011 - 54 months • Developing early diagnostic tests, laboratory-based early warning systems, predictive models and risk maps better surveillance as well as developing a community-based strategy to reduce dengue incidence in school aged children • 15 participants from 11 countries including Brasil, Sri Lanka and Singapore • DENFREE € 6 million EU contribution - Start 01/01/2012 - 60 months • Is identifying the key factors determining transmission, outcome of infection and epidemics of dengue fever, as well as developing of novel diagnostic tools to detect asymptomatic infections, and estimating the risk of virus spreading to uninfected areas • 15 participants from 11 countries including Cuba, Cambodia and French Polynesia 5 What is Horizon 2020? The EU’s 2014-20 programme for research & innovation A core part of Europe 2020, Innovation Union & European Research Area − Responding to the economic crisis to invest in future jobs and growth − Addressing people’s concerns about their livelihoods, safety and environment − Strengthening the EU’s global position in research, innovation and technology http://ec.europa.eu/research/horizon2020 6 HORIZON 2020 (2014-2020) • • • • European Research Council Future and Emerging Technologies Marie Skłodowska-Curie actions Research infrastructures •Excellent science • • • Leadership in enabling and industrial technologies Access to risk finance Innovation in SMEs •Industrial leadership •Societal challenges SC1- Health, demographic changes and wellbeing (€ 7.5 b) The new EU programme for research and innovation € 79 billion (2014-2020) Excellent science €24bn Health inMarie H2020 Skłodowska Future and Emerging Technologies European Research Council Curie Research Infrastructures Industrial leadership €17bn Fast Track to Innovation Eureka Eurostars-2 LEIT Biotech Financial instruments SC1 Health €7.5bn (of €31bn) SME instrument IMI-2 Collaborative projects AAL-2 EDCTP-2 8 Infectious Diseases R&I – Collaboration for innovative solutions – Implementation 1 – Collaborative research projects Implemented by DG RTD 2 - Horizon prize Implemented by DG RTD 3 – Global Initiatives GLOPID- R ; GTBVP; World RePORT 4- Public–Private partnership IMI2: From discovery to human testing to regulatory aspects, HTA and pharmacovigilence 5- Public–Public partnership EDCTP2 Joint Programme on AMR ERA-INFECT 6- Infectious Disease Finance Facility – INNOVFIN ID jointly developed by EC and EIB 9 Infectious diseases in Horizon 2020 COLLABORATIVE RESEARCH Priorities addressed in 2014-2015: • Vaccine development for poverty related and neglected infectious diseases • 2014 – Tuberculosis € 25 million – 2 projects funded • 2015 – HIV/AIDS € 45 million – 2 projects funded • 2014 – COMPARE - Development of web based system for rapid identification, containment and mitigation of emerging infectious diseases and foodborne outbreaks by generation and comparison of genomic information on samples and pathogens across sectors, time and locations, with contextual additional data. • 2014 - I-MOVE+,a scientific public health platform to identify, pilot test, use and disseminate the best study designs to measure the effectivenes (direct effect)and the impact (indirect and overall effect) of influenza and pneumococcal vaccines 10 The challenges • Ageing population • Increased disease burden • Unsustainable and unequal health & care systems • Health & care sector under pressure to reform 11 Who's eligible for funding? • Horizon 2020 is open to participation from across the world • By default: • • Member States (including overseas departments and overseas territories) • Associated Countries • exhaustive list of countries in annex to work programme (but: no longer BRIC + Mexico in this list!) Participants from other countries are funded in exceptional cases: • when provision is made in the call text • bilateral agreement (e.g. USA, Health challenge – NIH) • when the Commission deems it essential (case by case assessment) 12 The Horizon 2020 Health Challenge: WP 2016-2017 Understanding health, well-being & disease Preventing disease Treating and managing diseases 'Personalised Medicine' Active ageing and self-management of health Methods and data Health care provision and integrated care 'coordination activities' ERA-NETs , Joint Programming, Global Alliance for Chronic Diseases (GACD), Valorisation of FP7 results and other Coordination Actions € 930 million 13 Understanding the call topics: example • 'PHC 2 – 2015' • 'Specific challenge' • 'Scope' • 'Expected impact' • 'Type of action' 14 Topics 2016-2017 - 1.1 Understanding health, wellbeing and disease: • PM 01 – 2016 – Multi omics for personalised therapies [RTD] • PM 02 – 2017- New concepts in patient stratification [RTD] • PM 03 – 2016 – Diagnostic characterisation of rare diseases • PM 04 – 2016 - Networking and optimising the use of population and patient cohorts at EU level [RTD] 15 Topics 2016-2017 - 1.2 Preventing diseases: • PM-05–2016: The European Human Biomonitoring Initiative [RTD] • PM-06–2016: Vaccine development for malaria and/or neglected infectious diseases [RTD] • PM-07–2017: young Promoting mental well-being in the 16 Topics 2016-2017 - 1.3 Treating and managing diseases : • PM 08 – 2017 - New therapies for rare diseases [RTD] • PM 09 – 2016 - New therapies for chronic diseases [RTD] • PM 10 – 2017 - Comparing the effectiveness of existing healthcare interventions in the adult population [RTD] • PM 11 – 2016+2017 - Clinical research on regenerative medicine [RTD] 17 Topics 2016-2017 - 1.4 Active ageing and self-management of health: • PM 12 – 2016 – PCP – eHealth innovation in empowering the patient [CNECT] • PM 13 – 2016- PPI for deployment and scaling up of ICT solutions for active and healthy ageing [CNECT] • PM 14 – 2016 – EU-Japan cooperation on Novel ICT Robotics based solutions for active and healthy ageing at home or in care facilities [CNECT] • PM 15 – 2017 - Personalised coaching for well-being and care of people as they age [CNECT] 18 Topics 2016-2017 - 1.5 Methods and data: • PM 16 - 2017- In-silico trials for developing and assessing biomedical products [CNECT] • PM 17 – 2017 - Personalised computer models and in-silico systems for well-being [CNECT] • PM 18 – 2016 - Big Data supporting Public Health policies [CNECT] • PM 19 – 2017 - PPI for uptake of standards for the exchange of digitalised healthcare records [CNECT] • PM 20 - Development of new methods for improved economic evaluation and efficiency measures in the health sector [RTD] 1.6 Health care provision and integrated care: • PM 21 - 2016- Implementation research for scaling-up of evidence based innovations and good practice in Europe and middle-income countries [RTD] 19 Topics 2016-2017 - Coordination activities: • HCO 01 – 2016 - Valorisation of FP7 Health and H2020 SC1 research results [RTD] • HCO 02 – 2016 - Standardisation of pre-analytical and analytical procedures for in vitro diagnostics in personalised medicine [RTD] • HCO 03 – 2017 - Implementing the Strategic Research Agenda on Personalised Medicine [RTD] • HCO 04 – 2016 - Towards globalisation of the Joint Programming Initiative on Antimicrobial resistance [RTD] • HCO 05 – 2016 - Coordinating personalised medicine research [RTD] • HCO 06 – 2016 - Towards an ERA-NET for building sustainable and resilient health care models • HCO 07– 2017 - Global Alliance for Chronic Diseases (GACD) [RTD] • HCO 08 – 2017 - Actions to bridge the divide in European health research and innovation [RTD] 20 Topics 2016-2017 Co-ordination activities: • HCO 09 – 2016 - EU m-health hub including evidence for the integration of mHealth in healthcare systems [CNECT] • HCO 10 – 2016 - Support for Europe’s leading Health ICT SMEs [CNECT] • HCO 11– 2016 - Coordinated Action to support the recognition of Silver Economy opportunities arising from demographic change [CNECT] • HCO 12 – 2016 - Digital health literacy [CNECT] • HCO 13 – 2016 – Healthcare workforce IT skills [CNECT] • HCO 14 – 2016 - EU-US interoperability roadmap [CNECT] • HCO 15- 2016 - EU eHealth Interoperability conformity assessment [CNECT] • HCO 16- 2016 – Standardisation needs in the field of ICT for Active and Healthy Ageing [CNECT] 21 HORIZON PRIZE • The European Commission has launched the: Horizon Prize for Better use of Antibiotics • This challenge prize is offering a cash reward of €1 million • To the person or team who can most effectively meet the following challenge: Develop a rapid test that will allow healthcare providers to distinguish, at the point-of-care, between patients with upper respiratory tract infections that require antibiotics and those that can be treated safely without them Upper Respiratory Tract Infections include pharyngitis, sinusitis, otitis and bronchitis 22 GLOPID-R A Global Research Collaboration for Infectious Disease Preparedness • A global multifunder initiative • A network of research funders which aims to spark a collaborative global research response within 48 hours, after an outbreak • Key funders from Australia, Brazil, Canada, China, South Africa, US, France, UK, Sweden, Spain, Germany 23 GloPID-R objectives Facilitate exchange of information Address scientific, legal, ethical and financial challenges Implement a 'One Health' approach with close cooperation between human and animal health researchers Establish a strategic agenda for research response Connect infectious disease research networks Create partnerships with low-income countries 24 EDCTP2 (2014 – 2024) • Broader scope: support to clinical trials to bring treatments, vaccines, diagnostics and delivery optimisation closer to the patients of HIV/AIDS, TB, malaria and neglected infectious diseases • More EU co-funding €683 million from EU Horizon2020 + at least the same amount from participating countries • Governance 28 full member countries: 14 African + 14 European countries • Publication of work plan 2015 http://www.edctp.org 25 Diseases: HIV/AIDS, TB, Malaria, NIDs, emerging infectious diseases of particular relevance for Africa, including Ebola New tools and interventions: Diagnostics, drugs, vaccines and microbicides Capacity Development: Fellowships, Networks, Ethics, Regulatory General rules for participation: At least 2 legal entity in EU Member States or in countries associated to Horizon 2020 and one legal entity in Sub Saharan Africa 26 Get prepared! Free of charge services to assist you: • Call text, guide for applicants, FAQs: Participant portal http://ec.europa.eu/research/participants/portal/desktop/en/home.html • Practical information & assistance: National Contact Points (NCPs), Enterprise Europe Network (EEN) http://ec.europa.eu/research/participants/portal/desktop/en/support/national_contact_points.ht ml • Find partners, training, brokerage: Fit for Health 2.0 http://www.fitforhealth.eu/ • Projects funded in FP7 Health: EU Health projects database http://www.healthcompetence.eu/converis/publicweb/area/1353 • IP questions and advices: IPR helpdesk https://www.iprhelpdesk.eu/ • • SME regulatory one stop shop: EMA SME office http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000059.jsp Become evaluator - select the best projects http://ec.europa.eu/research/participants/portal/desktop/en/experts/index.html 27 Thank you www.ec.europa/research/horizon2020 http://ec.europa.eu/research/health/infectious-diseases/index_en.html 28